Premium
CLINICAL OUTCOMES FROM VENETOCLAX BASED THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL LYMPHOMAS
Author(s) -
Lewis K.L.,
Dowling M.,
Bavishi K.,
Øvlisen A.K.,
Hamad N.,
Choi P.,
Grigg A.,
P'Ng S.,
Filshie R.,
Ritchie D.S.,
Bilmon I.,
Prince H.M.,
Wolf M.,
Hertzberg M.,
Chuah H.,
ElGalaly T.C.,
Tam C.S.,
Seymour J.F.,
Cheah C.Y.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.221_2631
Subject(s) - venetoclax , medicine , lymphoma , bendamustine , oncology , follicular lymphoma , chronic lymphocytic leukemia , refractory (planetary science) , ibrutinib , salvage therapy , aggressive lymphoma , rituximab , gastroenterology , leukemia , chemotherapy , physics , astrobiology